HIMS, in September, had announced access to the most common compounded GLP-1 subscriptions for $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. The company ...

Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Hims' GLP-1 drugs start at $199 a month, while Wegovy and Ozempic cost over $900 a month — though the price many patients pay depends on their insurance. Earlier this month, Hims ran a Super ...

the stock had been very strong in the past few months, and a lot of investors wanted to take profits during a shaky market. Secondly, HIMS' EBITDA margins weren't as strong as one would have expected.

Telehealth company Hims & Hers (HIMS) saw a major boost in app downloads during February. According to a Top-rated analyst, Craig ...

Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 11 cents in fourth-quarter 2024, compared with the year-ago period’s EPS of a penny. However, the metric missed the Zacks ...

Telehealth company Hims & Hers Health (NYSE:HIMS) announced in Q4 CY2024, with sales up 95.1% year on year to $ ... to grow 42.2% over the next 12 months, a deceleration versus the last two years.

Direct-to-consumer telehealth company Hims & Hers is forging ahead in the aftermath of the semaglutide shortage ending last week. Hims & Hers faces new headwinds in its weight management segment ...

So, while it may be a good idea to avoid the HIMS stock for now, keep an eye on it. The drugs, collectively known as semaglutide, were in short supply in the U.S. for months thanks to a massive ...